Hedge funds are buying these two big tech stocks while selling two rivals
Director Bridgette P. Heller of Dexcom Inc (NASDAQ:DXCM) sold 1,012 shares of common stock on November 12, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a price of $58.07, for a total transaction value of $58,766.
Following the transaction, Heller directly owns 27,031 shares of Dexcom.
The sale was executed under a pre-arranged 10b5-1 trading plan adopted by Heller on August 14, 2025. This plan allows for the orderly disposition of shares. The sale was reported by Jereme M. Sylvain, as Attorney-in-Fact for Bridgette P. Helle
In other recent news, DexCom reported its third-quarter earnings for 2025, exceeding analysts’ expectations with an earnings per share (EPS) of $0.61 against a forecasted $0.57, marking a 7.02% earnings surprise. The company also reported revenue of $1.21 billion, surpassing predictions of $1.18 billion, which represents a 2.54% surprise. Despite this positive performance, several analyst firms adjusted their price targets for DexCom. Bernstein lowered its price target to $84 due to valuation concerns, while maintaining an Outperform rating. Piper Sandler reduced its target to $75, citing growth concerns, but kept an Overweight rating. BTIG also adjusted its price target to $85, maintaining a Buy rating after noting a 20% organic year-over-year revenue growth. Canaccord Genuity decreased its target to $99, highlighting quality costs, but continued with a Buy rating. These recent developments reflect differing analyst perspectives on DexCom’s future growth and valuation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.